Merck Meets Primary Endpoints in Phase 3 in Urothelial Cancer

 First Phase 3 results for the KEYTRUDA® (pembrolizumab) and Padcev® (enfortumab vedotin-ejfv) combination showed a statistically significant and clinically meaningful improvement in OS, PFS and key secondary endpoint of overall response rate versus chemotherapy in these patients, who may or may not be eligible for cisplatin-based chemotherapy

https://finance.yahoo.com/news/merck-announces-phase-3-keynote-100000777.html